9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesotherioma

Estimated Enrollment: 12

Gender: All

Min Age: 20 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate,  Duration of response,  Progression free survival, Median survival time

Interventions: Pemetrexed, Cisplatin

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date:

Completion Date: August 2006

Last  Posted Date: November 6, 2007

Location: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon – Fri from 9 AM to 5 PM Eastern Time (UTC/GMT – 5 hours, EST), or speak with your personal physician, Aichi, Japan

Website Link: https://ClinicalTrials.gov/show/NCT00251550

Was this article helpful?
Dislike 0